- Home
- RPT vs APLT Comparison
RPT vs APLT Comparison
Compare RPT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPT
- APLT
- Stock Information
- Founded
- RPT 2014
- APLT 2016
- Country
- RPT United States
- APLT United States
- Employees
- RPT N/A
- APLT N/A
- Industry
- RPT
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- RPT
- APLT Health Care
- Exchange
- RPT NYSE
- APLT Nasdaq
- Market Cap
- RPT 124.9M
- APLT 128.0M
- IPO Year
- RPT N/A
- APLT 2019
- Fundamental
- Price
- RPT $2.73
- APLT $0.69
- Analyst Decision
- RPT Strong Buy
- APLT Buy
- Analyst Count
- RPT 1
- APLT 7
- Target Price
- RPT $4.00
- APLT $6.10
- AVG Volume (30 Days)
- RPT 173.9K
- APLT 7.0M
- Earning Date
- RPT 01-01-0001
- APLT 03-05-2025
- Dividend Yield
- RPT 9.02%
- APLT N/A
- EPS Growth
- RPT N/A
- APLT N/A
- EPS
- RPT N/A
- APLT N/A
- Revenue
- RPT N/A
- APLT N/A
- Revenue This Year
- RPT N/A
- APLT N/A
- Revenue Next Year
- RPT $6.99
- APLT $2,622.90
- P/E Ratio
- RPT N/A
- APLT N/A
- Revenue Growth
- RPT N/A
- APLT N/A
- 52 Week Low
- RPT $2.65
- APLT $0.60
- 52 Week High
- RPT $6.01
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- RPT N/A
- APLT 21.46
- Support Level
- RPT N/A
- APLT $0.60
- Resistance Level
- RPT N/A
- APLT $0.73
- Average True Range (ATR)
- RPT 0.00
- APLT 0.09
- MACD
- RPT 0.00
- APLT 0.23
- Stochastic Oscillator
- RPT 0.00
- APLT 27.85
About RPT RITHM PROPERTY TRUST INC
Rithm Property Trust Inc is a real estate investment trust (REIT) externally managed by an affiliate of Rithm Capital Corp. (Rithm). The group is embarking on a new commercial real estate-focused investment. Its tailored approach to investment management seeks to generate attractive risk-adjusted returns for stockholders over the long term through dividends and capital appreciation.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.